Since its establishment in 1982, Mediscience Planning Inc. has endeavored to provide higher-quality assistance for the development of medical products as a pioneer contract research organization (CRO). We currently provide a wide variety of services related to medical product development, including data management centering on monitoring, pharmacovigilance, medical writing and consulting, and contract sales organization (CSO) services. We have developed a system that ensures we can provide a one-stop service according to customers’ requirements from the initial phase of product development to services after production and sale. In October 2008, the company was listed on the Hercules Market of the Osaka Securities Exchange.
The CRO business has constantly grown through pharmaceutical companies’ energetic research activities and the increasing outsourcing of this research. We expect that the roles and responsibilities of CROs will further expand and diversify at the stage of medical product development.
From the fiscal year ending in August 2010, Mediscience Planning has established and promoted Action Plan 30, a three-year medium-term plan based on the three pillars of “building a strong organization,” “clear differentiation from competitors,” and “preparation for the next generation.” Through the combined efforts of all our staff in the promotion of Action Plan 30, we aim to improve our corporate value, realize our management ideal of contributing to the soundness of society, and do our best to fulfill our social obligations as a listed company.

Chairman CEO　Akinori Urae
President COO　Kyoro Sakai